KALV - KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa.

Sector

Healthcare

Industry

Biotechnology

Market Cap

$1.44B

Beta

-0.29

52-Week Range

9.83-27

CEO

Benjamin L. Palleiko

Employees

275

IPO Date

Apr 9, 2015

Exchange

NASDAQ

KALV Options Snapshot

Options pricing data for KALV is refreshed daily after the close. When listed contracts exist, this page surfaces the latest at-the-money implied volatility, max pain strike, dealer gamma exposure (GEX), and 25-delta skew. Listed contracts and live snapshots appear once the options chain has been published by the exchange for the most recent session.

What This Page Covers

The KALV overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.